Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors combination therapy versus monotherapy and major adverse cardiovascular events: Do the benefits add up?
Published: 8 July 2024
Author(s): Paschalis Karakasis, Dimitrios Patoulias, Nikolaos Fragakis, María Rosa Bernal-López, Ricardo Gómez-Huelgas
